Skip to main content
Fig. 3 | Allergy, Asthma & Clinical Immunology

Fig. 3

From: Indirect treatment comparison of oral sebetralstat and intravenous recombinant human C1 esterase inhibitor for on-demand treatment of hereditary angioedema attacks

Fig. 3

Time to beginning of symptom relief matched for A baseline attack severitya only and B baseline attack severity,a age, sex, and race. aMaximum of three baseline Overall Severity visual analog scale (VAS) scores. bHazard ratio (HR) values > 1 favor sebetralstat 300 mg over rhC1INH 50 IU/kg. CI, confidence interval; rhC1INH, recombinant human C1 esterase inhibitor; MA, meta-analysis; MAIC, matching-adjusted indirect comparison

Back to article page

Allergy, Asthma & Clinical Immunology

ISSN: 1710-1492

Contact us